Melbourne - Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a successful $175 million1 institutional placement of new, fully paid ordinary shares in the Company (New Shares) at a price of $7.70 per New Share (Placement).
The Placement will be followed by a Share Purchase Plan (SPP) to raise up to $25 million at the same offer price.
Following completion of the Placement and SPP, Telix will be well funded to execute on its late- stage clinical product pipeline and advance multiple programs towards commercialisation, particularly the ProstACT (prostate cancer therapy) clinical program. The Company also intends to use the additional funds to further expand its pipeline and capabilities around Targeted Alpha Therapy (TAT). These activities are in parallel to launch of Telix's first commercial product Illuccix (kit for the preparation of gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection), which recently attained a marketing authorisation from the U.S. Food and Drug Administration (FDA).
Telix Group CEO Dr Christian Behrenbruch stated, 'We are delighted with the level of support for the Placement from new and existing investors. Funds raised under the Placement and SPP will provide the Company with the financial resources to execute on the next phase of Telix's growth strategy, which is to advance our core therapeutic clinical programs, expand our commercial diagnostic portfolio and proactively seek out new innovations that will cement Telix's position as a leader in the field of 'theranostic' radiopharmaceuticals.
'We are particularly pleased to attract high quality, specialist investors to the register and would like to welcome our new investors and thank our existing shareholders for their outstanding support.'
Placement
The Placement is being made to new and existing investors and comprises the issue of approximately 22,727,273 New Shares at an offer price of $7.70 per New Share (Offer Price). The Offer Price represents a 4.8% discount to the closing price of shares on ASX as at close of trading on Wednesday, 19 January 2022 and an 8.8% discount to the 5-day volume weighted average price (VWAP) up to and including Wednesday, 19 January 2022. No shareholder approval is required for the Placement, as the Company will utilise a portion of its existing placement capacity under ASX Listing Rule 7.1. Shares issued under the Placement will rank equally with Telix's existing shares.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Telix's lead product, gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection for prostate cancer imaging, has been approved by the U.S. Food and Drug Administration (FDA),2 and by the Australian Therapeutic Goods Administration (TGA).3 Telix is also progressing marketing authorisation applications for this investigational candidate in Europe4 and Canada.5
Contact:
Email: kyahn.williamson@telixpharma.com
Important Information
This announcement is not financial product or investment advice, a recommendation to acquire securities, or accounting, legal or tax advice. It does not constitute an invitation or offer to apply for securities. It has been prepared without taking into account the objectives, financial or tax situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate for their jurisdiction. Telix is not licensed to provide financial product advice in respect of its securities.
This announcement has been prepared for publication in Australia and may not be released to U.S. wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws
TELIX PHARMACEUTICALS LIMITED 
